SG Americas Securities LLC Sells 96,511 Shares of Trevi Therapeutics, Inc. $TRVI

SG Americas Securities LLC lessened its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 77.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 28,051 shares of the company’s stock after selling 96,511 shares during the quarter. SG Americas Securities LLC’s holdings in Trevi Therapeutics were worth $335,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. raised its stake in Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after buying an additional 2,996 shares in the last quarter. Hilton Head Capital Partners LLC bought a new stake in Trevi Therapeutics during the 4th quarter valued at $40,000. Caitong International Asset Management Co. Ltd bought a new stake in Trevi Therapeutics during the 4th quarter valued at $50,000. Strs Ohio purchased a new position in shares of Trevi Therapeutics in the 1st quarter valued at $52,000. Finally, Rafferty Asset Management LLC purchased a new position in shares of Trevi Therapeutics in the 2nd quarter valued at $60,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $18.40 on Friday. The stock’s fifty day moving average price is $15.41 and its 200 day moving average price is $13.12. Trevi Therapeutics, Inc. has a 1 year low of $6.03 and a 1 year high of $20.15. The company has a market cap of $2.61 billion, a price-to-earnings ratio of -57.50 and a beta of 1.00.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Research analysts expect that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. JonesTrading reduced their price target on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. D. Boral Capital reiterated a “buy” rating and issued a $19.00 target price on shares of Trevi Therapeutics in a report on Friday, April 17th. Morgan Stanley reissued an “overweight” rating and set a $20.00 price target on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Trevi Therapeutics in a report on Wednesday, May 20th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Trevi Therapeutics has an average rating of “Buy” and a consensus target price of $22.67.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.